30th week of 2018 patent applcation highlights part 23 |
Patent application number | Title | Published |
20180208589 | LMP7 INHIBITORS - The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2018-07-26 |
20180208590 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF - The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions. | 2018-07-26 |
20180208591 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS - The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2018-07-26 |
20180208592 | BENZOQUINOLONE INHIBITORS OF VMAT2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. | 2018-07-26 |
20180208593 | 4-Azaindole Derivatives - 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient. | 2018-07-26 |
20180208594 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER - Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): | 2018-07-26 |
20180208595 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS - Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity. | 2018-07-26 |
20180208596 | Solid Forms and Formulations of Imidazopyrazine Compound - In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents. | 2018-07-26 |
20180208597 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES - The invention relates to new compounds of formula (I) that are useful in medicine, specifically in treating or preventing cancerous diseases in a mammal, to pharmaceutical compositions comprising such compounds, optionally together with other pharmaceutically active compounds, or to pharmaceutical formulations comprising such compounds or pharmaceutical compositions. The invention further relates to methods of making these compounds. | 2018-07-26 |
20180208598 | PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF - Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-γ production in vivo. A compound represented by formula (I) [wherein X represents —CH═CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof. | 2018-07-26 |
20180208599 | Novel polymorphs of ponatinib hydrochloride - Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. | 2018-07-26 |
20180208600 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF - The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases. | 2018-07-26 |
20180208601 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS - The invention provides novel compounds having the general formula (I) | 2018-07-26 |
20180208602 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS - The invention provides novel compounds having the general formula (I) | 2018-07-26 |
20180208603 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases. | 2018-07-26 |
20180208604 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF - Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase. | 2018-07-26 |
20180208605 | Substituted Aza Compounds as IRAK-4 Inhibitors - The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4. | 2018-07-26 |
20180208606 | HISTONE DEACETYLASE INHIBITORS - This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3). | 2018-07-26 |
20180208607 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS - The present invention provides, in part, compounds of Formula I: | 2018-07-26 |
20180208608 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS - The present invention provides, in part, heterocyclic spiro compounds of Formula I: | 2018-07-26 |
20180208609 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2018-07-26 |
20180208610 | COMPOSITIONS HAVING ADHESION PROPERTIES - Compositions of matter that have adhesion properties. The presence of a large number of silanols on the molecules described herein creates a solubility or disperseability of these molecules in aqueous solutions that is not obtainable from random hydrolysis of the precursor silanes. | 2018-07-26 |
20180208611 | METHOD FOR PREPARING INORGANIC/ORGANIC HYBRID PEROVSKITE COMPOUND FILM - The present invention relates to a method for preparing an inorganic/organic hybrid perovskite compound film, and a structure for a solar cell and, specifically, a method for preparing an inorganic/organic hybrid perovskite compound film, according to one embodiment of the present invention, can comprise the steps of: a) forming, on a substrate layer, an adduct layer containing an adduct of halogenated metal and guest molecule; and b) preparing an inorganic/organic hybrid perovskite compound film by reacting the adduct layer and an organic halide. | 2018-07-26 |
20180208612 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS - Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition. | 2018-07-26 |
20180208613 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS - Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition. | 2018-07-26 |
20180208614 | CRYSTAL OF CYCLIC PHOSPHONIC ACID SODIUM SALT AND METHOD FOR MANUFACTURING SAME - An object of the present invention is to provide a crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1): | 2018-07-26 |
20180208615 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A metal tetradentate complex is disclosed in which an imidazole moiety is used as a linker in the ligand. The complex is useful as an emitter or other functional roles in an OLED device. | 2018-07-26 |
20180208616 | DINITROSYL IRON COMPLEX, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, COMPOSITE MATERIAL COMPRISING THE SAME, AND USES THEREOF - Disclosed herein are novel compounds of formula (I) and (II), each of which may serve as a reagent to deliver nitric oxide (NO) and a therapeutic agent to treat NO-associated diseases. Also disclosed are a pharmaceutical composition comprising the compound of formula (I) or (II), a composite material comprising the compound of formula (I) or (II), and the uses thereof. | 2018-07-26 |
20180208617 | TUNGSTEN PRECURSOR, AND METHOD FOR DEPOSITING TUNGSTEN-CONTAINING FILM COMPRISING SAME - The present invention relates to a tungsten precursor compound to which a substituent is bonded so as to obtain thermal stability and a tungsten-containing film in a mild condition at a high yield, and a process for producing the same. The present invention also provides a method for depositing tungsten-containing film. | 2018-07-26 |
20180208618 | NOVEL SUGAR DERIVATIVE GELATORS - A novel gelator including a sugar derivative; a gelator including a compound of Formula (1) or Formula (2): | 2018-07-26 |
20180208619 | SYNTHESES, ACTIVITIES, AND METHODS OF USE OF DIHYDRONICOTINAMIDE RIBOSIDE DERIVATIVES - Disclosed is a compound of formula (I): | 2018-07-26 |
20180208620 | TUNICAMYCIN RELATED COMPOUNDS WITH ANTI-BACTERIAL ACTIVITY - Tunicamycin related compounds having an acyl chain double bond reduced and/or having an acyl chain double bond and an uracil ring double bond reduced are described as well as methods of making these tunicamycin related compounds. These tunicamycin related compounds are not toxic to eukaryotic cells and can be used to kill Gram-positive bacteria, alone or in combination with other antibiotics. Use of these tunicamycin related compounds to kill Gram-positive bacteria, treat Gram-positive bacterial diseases, and disinfect objects or surfaces are described. In addition, naturally-occurring streptovirudin compounds are not toxic to eukaryotic cells and can be used to kill Gram-positive bacteria, alone or in combination with other antibiotics. | 2018-07-26 |
20180208621 | NUCLEOTIDES FOR THE TREATMENT OF CANCER - The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim | 2018-07-26 |
20180208622 | STABLE CRYSTALLINE FORM OF REGADENOSON - The present invention provides crystalline Form S of regadenoson which is substantially free of residual organic solvent and having an X-ray powder diffraction pattern comprising characteristic peak at 10.3, 10.8, 19.0, 21.6 and 25.5±0.2 degrees | 2018-07-26 |
20180208623 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL - Described herein are solid state 17α-ethynylandrost-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17α-ethynylandrost-5-ene-3β,7β,17β-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients. | 2018-07-26 |
20180208624 | Protein Separations Using An Acrylamide Containing Filter - Novel compositions for removing impurities such as, protein aggregates, from a sample containing a protein of interest, e.g., an antibody. Such compositions can be used prior to the virus filtration step during protein purification, to remove aggregates and protect the virus filter from fouling, therefore improving virus filter capacity. A porous solid support including a co-polymer having at least two monomers, wherein at least one of the monomers comprises acrylamide and at least a second monomer comprises a hydrophobic binding group, where the solid support selectively binds protein aggregates, thereby to separate the monomeric protein of interest from the protein aggregates. The method can be performed under neutral to high pH and high conductivity conditions. | 2018-07-26 |
20180208625 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE - Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided. | 2018-07-26 |
20180208626 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein. | 2018-07-26 |
20180208627 | HYDROCARBON-STAPLED POLYPEPTIDES FOR ENHANCEMENT OF ENDOSOME-LYSOSOMAL DEGRADATION - The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds. | 2018-07-26 |
20180208628 | NEW SPECIES OF TOBAMOVIRUS - The present invention provides a new species of tobamovirus and its use to identify plants comprising resistance against the virus. | 2018-07-26 |
20180208629 | COMPOSITION FOR PREVENTING MYCOPLASMA SPP. INFECTION - The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against | 2018-07-26 |
20180208630 | FUSION PROTEINS AND METHODS FOR STIMULATING PLANT GROWTH, PROTECTING PLANTS, AND IMMOBILIZING BACILLUS SPORES ON PLANTS - The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a | 2018-07-26 |
20180208631 | PESTICIDAL TOXIN PROTEINS ACTIVE AGAINST LEPIDOPTERAN INSECTS - Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample. | 2018-07-26 |
20180208632 | MUTANT LYSENIN PORES - The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin. | 2018-07-26 |
20180208633 | Peptide Compounds and Methods of Production and Use Thereof - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptide compounds. | 2018-07-26 |
20180208634 | Recoverin as a Fusion Protein Tag to Improve Expression, Solubility and Purification of Proteins - Herein presented is a new, versatile fusion protein tool (tag) to improve the solubility and purification of proteins. Particularly, the fusion tag is the substantially full-length (about 23 kD) Recoverin molecule (TagR) that is used for protein purification in a single step, even in the presence of detergents. | 2018-07-26 |
20180208635 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF - The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45A (Angstroms) or less. | 2018-07-26 |
20180208636 | BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF - The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided. | 2018-07-26 |
20180208637 | METHODS OF IDENTIFYING, ISOLATING AND USING ODORANT AND AROMA RECEPTORS - Provided here are new methods to identify specific families of mammalian odorant receptors for odorants or aroma, particularly indole and skatole malodors and their use in assays that may be used to discover compounds that modulate (blocking, enhancing, masking or mimicking compounds) their activity. Orphan mouse odorant receptors are identified from olfactory sensory neurons that respond to target compounds. The resulting receptors as well as their human counterparts can be screened in assays against test compounds to confirm their identity as odorant or aroma receptors, particularly malodor receptors and subsequently discover for example modulators that inhibit the perception of the malodor in humans. | 2018-07-26 |
20180208638 | T CELL RECEPTORS - The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention. | 2018-07-26 |
20180208639 | CTLA-4 Variants - Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life. | 2018-07-26 |
20180208640 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2018-07-26 |
20180208641 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2018-07-26 |
20180208642 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TARGETING PEPTIDE-ELASTIN FUSION POLYPEPTIDES AND THEIR SELF-ASSEMBLED NANOSTRUCTURES - Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide. | 2018-07-26 |
20180208643 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 2018-07-26 |
20180208644 | ANTI-SEMAPHORIN 3A ANTIBODY AND TREATMENT OF ALZHEIMER'S DISEASE AND INFLAMMATORY IMMUNE DISEASES USING SAME - The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease. | 2018-07-26 |
20180208645 | Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy - Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed. | 2018-07-26 |
20180208646 | ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG4-5 - The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications. | 2018-07-26 |
20180208647 | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 2018-07-26 |
20180208648 | GDF11 BINDING PROTEINS AND USES THEREOF - Binding proteins that specifically bind to GD-F11 prodomain complex are disclosed. In some embodiments, antibodies that specifically bind to GDF11 prodomain complex are disclosed. These binding proteins may be used to treat or to prevent diseases caused by aberrant levels or activities of GDF11. | 2018-07-26 |
20180208649 | METHODS FOR DIAGNOSING AND TREATING AFFECTIVE DISORDERS - The methods of the present invention are useful for determining whether an individual has or is at risk of developing an affective disorder by detecting the expression level of connective tissue growth factor (CTGF) in a biological sample. The methods of the present invention are also useful for identifying compounds that modulate (e.g., decrease) the expression level or activity of CTGF. The present invention further provides therapeutic methods that target CTGF for the treatment of an affective disorder. | 2018-07-26 |
20180208650 | BONE-TARGETING ANTIBODIES - Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed. | 2018-07-26 |
20180208651 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING POLYPEPTIDES AND/OR PROTEINS - Embodiments of the invention provide shaped masses (SM) comprising one or more drugs such as proteins or polypeptides and methods for forming and delivering such SM's. One embodiment provides a SM comprising a drug e.g., a protein or polypeptide having a biological activity in the body of a mammal. The SM is formed by compression of a precursor material (PM) comprising the drug wherein an amount of biologically active drug in the SM is a minimum level to that in the PM. Drugs which may be incorporated into the SM include insulin, incretins and immunoglobulins e.g., interleukin neutralizing antibodies or TNF-α-inhibiting antibodies. Embodiments of the invention are particularly useful for the oral delivery of drugs which would be degraded within the GI tract, wherein the SM containing the drug is formed as or incorporated into a tissue penetrating member which is inserted into the intestinal wall after oral ingestion. | 2018-07-26 |
20180208652 | ANTI-KIR ANTIBODIES, FORMULATIONS, AND USES THEREOF - A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer. | 2018-07-26 |
20180208653 | METHODS FOR ENHANCING AN IMMUNE RESPONSE - Methods and compositions for enhancing an immune response in a subject (e.g., an immunocompromised subject or a subject with systemic lupus erythematosus (SLE)) are described. In particular, methods of administering to the subject an effective amount of an anti-signaling lymphocytic activation molecule family member 7 (SLAMF7)-antibody or antigen binding fragment thereof are described. | 2018-07-26 |
20180208654 | Antibodies Targeting CDH19 for Melanoma - The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct. | 2018-07-26 |
20180208655 | ANTI-GPNMB ANTIBODIES AND DIAGNOSTIC USES THEREOF - The present application discloses anti-GPNMB antibodies and methods of using the same. The antibodies are selected to bind to an epitope located in a C-terminal fragment of the protein and are selected for specificity in immunohistochemical assays. The antibodies are useful in, for example, immunohistochemical methods of detecting GPNMB-positive cells in tumors. | 2018-07-26 |
20180208656 | Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof - The present invention provides antibodies that bind to prokineticin receptors (PROKRs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PROKR1 and/or PROKR2. The present invention includes antibodies that bind cell surface-expressed PROKR1 and/or PROKR2. In certain embodiments, the antibodies of the present invention are capable of blocking prokineticin (PK)-mediated activation of one or more PROKR. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling. | 2018-07-26 |
20180208657 | RECOMBINANT ANTIBODY MOLECULE AND ITS USE FOR TARGET CELL RESTRICTED T CELL ACTIVATION - The present disclosure relates to a recombinant antibody molecule, bispecific as well as tri-specific hetero-dimeric antibody molecules, as well as a method for producing the same, its use and a nucleic acid molecule encoding the recombinant antibody molecules. The disclosure in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells. | 2018-07-26 |
20180208658 | CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF - The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an AFP peptide and an MHC class I protein. Also provided are methods of making and using these constructs. | 2018-07-26 |
20180208659 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF - Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided. | 2018-07-26 |
20180208660 | DUAL-TARGET ANTIBODY TARGETING VEGFR-2 AND DLL4, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME - The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody. | 2018-07-26 |
20180208661 | AGENTS THAT NEUTRALIZE IL-3 SIGNALLING AND USES THEREOF - The present disclosure relates to compounds that are able to bind to an interleukin (IL)-3Rα chain and neutralize IL-3 signalling and uses thereof. | 2018-07-26 |
20180208662 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2018-07-26 |
20180208663 | IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES - Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same. | 2018-07-26 |
20180208664 | ANTI-CD95L ANTIBODY - The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases. | 2018-07-26 |
20180208665 | Anti-GITR Antigen-Binding Proteins and Methods of Use Thereof - Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods. | 2018-07-26 |
20180208666 | ANTI-OX40 ANTIBODIES AND DIAGNOSTIC USES THEREOF - The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot. | 2018-07-26 |
20180208667 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME - Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity. | 2018-07-26 |
20180208668 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2018-07-26 |
20180208669 | BLOCKING CD38 USING ANTI-CD38 F(ab')2 TO PROTECT NK CELLS - Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′) | 2018-07-26 |
20180208670 | METHODS FOR ENHANCING ANTI-TUMOR ANTIBODY THERAPY - Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells. | 2018-07-26 |
20180208671 | ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS - The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intra-cellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3ζ intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. | 2018-07-26 |
20180208672 | ANTIBODIES SPECIFIC TO HETERODIMERS OF BCL-2 FAMILY AND USES THEREOF - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient. | 2018-07-26 |
20180208673 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 2018-07-26 |
20180208674 | COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING ANTIBODIES FOR TREATING CANCER - A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer. | 2018-07-26 |
20180208675 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR - The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated. | 2018-07-26 |
20180208676 | Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability - Disclosed are methods of enhancing prostate cancer vulnerability to an anti-PSMA targeted therapy by administering an anti-androgen therapy to a subject so that the prostate cancer vulnerability in the subject is enhanced 2-4 weeks after the administration of the anti-androgen therapy and then administering to the subject an antibody or antigen binding fragment thereof that is capable of binding to the extracellular domain of PSMA after the prostate cancer vulnerability is enhanced. The anti-androgen therapy can be a hormonal therapy or surgical castration. The antibody or antigen binding fragment thereof may optionally be conjugated to a cytotoxic agent, e.g., Lutetium-177. | 2018-07-26 |
20180208677 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 2018-07-26 |
20180208678 | METHODS AND COMPOSITION FOR MODIFYING ENZYMES - Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at least one substrate, the method comprising: contacting the enzyme with a polypeptide library comprising a plurality of EBPs that bind different epitopes of the enzyme; identifying EBPs that bind to the enzyme to form an EBP-enzyme complex; assaying for the activity level and substrate specificity of the EBP-enzyme complex; and identifying EBPs that modify the substrate specificity of the enzyme by identifying EBPs that, when in an EBP-enzyme complex, have a different substrate specificity than un-complexed EBP; wherein the catalytic rate constant of the EBP-enzyme complex is ≥50% of the un-complexed enzyme for at least one substrate and/or wherein the EBP-enzyme complex retains binding to a substrate. | 2018-07-26 |
20180208679 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2018-07-26 |
20180208680 | Antibodies for Botulinum Neurotoxins - The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2018-07-26 |
20180208681 | COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES - Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment. | 2018-07-26 |
20180208682 | Starch Extraction - The present invention relates to a process for extraction of cassava starch. Particularly, the present invention relates to a process for extraction of cassava starch with a device. More particularly, the present invention relates to a process for extraction starch with a device and one or more enzymes. | 2018-07-26 |
20180208683 | METHOD FOR PREPARING SUGAMMADEX SODIUM - A process for preparing sugammadex sodium comprising:
| 2018-07-26 |
20180208684 | PREPARATION METHOD OF ANIONIC POLYMERIZATION INITIATOR, DEVICE FOR MANUFACTURING ANIONIC POLYMERIZATION INITIATOR AND ANIONIC POLYMERIZATION INITIATOR PREPARED THEREFROM - An method for preparing an anion polymerization initiator, a device for preparing the same and an anion polymerization initiator prepared therefrom are provided. And the method for preparing an anion polymerization initiator according to present invention is characterized in that an amine compound of Formula 1 and/or Formula 2; an organometallic compound; and/or a conjugated diene compound are introduced in the form of a solution and reacted. | 2018-07-26 |
20180208685 | CATALYST FOR PRODUCTION OF CONJUGATED DIOLEFIN AND METHOD FOR PRODUCING SAME - A supported molded catalyst having increased hardness, the supported molded catalyst being capable of improving the long-term stability of a reaction for producing a conjugated diolefin by catalytic oxidative dehydrogenation from a mixed gas including a monoolefin having 4 or more carbon atoms and molecular oxygen; and a method for producing the catalyst is provided. A molded catalyst for conjugated diolefin production, the molded catalyst being a catalyst for producing a conjugated diolefin by a catalytic oxidative dehydrogenation reaction from a mixed gas including a monoolefin having 4 or more carbon atoms and molecular oxygen, and being produced by molding a composite metal oxide and a glass fiber-like inorganic auxiliary agent. | 2018-07-26 |
20180208686 | COPOLYMERIZATION OF ELEMENTAL SULFUR TO SYNTHESIZE HIGH SULFUR CONTENT POLYMERIC MATERIALS - Copolymerization of elemental sulfur with functional comonomers afford sulfur copolymers having a high molecular weight and high sulfur content. Nucleophilic activators initiate sulfur polymerizations at relative lower temperatures and in solutions, which enable the use of a wider range of comonomers, such as vinylics, styrenics, and non-homopolymerizing comonomers. Nucleophilic activators promote ring-opening reactions to generate linear polysulfide intermediates that copolymerize with comonomers. Dynamic sulfur-sulfur bonds enable re-processing or melt processing of the sulfur polymer. Chalcogenide-based copolymers have a refractive index of about 1.7-2.6 at a wavelength in a range of about 5000 nm-8μιτι. The sulfur copolymer can be a thermoplastic or a thermoset for use in elastomers, resins, lubricants, coatings, antioxidants, cathode materials for electrochemical cells, dental adhesives/restorations, and polymeric articles such as polymeric films and free-standing substrates. Optical substrates are constructed from the chalcogenide copolymer and are substantially transparent in the visible and infrared spectrum. | 2018-07-26 |
20180208687 | RUBBER COMPOSITION FOR PNEUMATIC TIRES - Provided are a rubber composition for pneumatic tires with excellent fluidity and excellent degradation resistance, and a pneumatic tire formed from the rubber composition. The present invention relates to a rubber composition for pneumatic tires containing a rubber component including a halogenated butyl rubber, and an organic peroxide. | 2018-07-26 |
20180208688 | METHOD FOR SURFACE MODIFICATION OF NANOPARTICLES - A method for surface modification of nanoparticles includes the separate steps of removing ligands from the surface of the nanoparticles to form ligand-free nanoparticles, and mixing new ligands with the ligand-free nanoparticles to form modified nanoparticles. | 2018-07-26 |